Should You Buy Coeptis Therapeutics Holdings Inc (COEP) Stock on Tuesday?

Overall market sentiment has been down on Coeptis Therapeutics Holdings Inc (COEP) stock lately. COEP receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Coeptis Therapeutics Holdings Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on COEP!

See Full COEP Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With COEP Stock Today?

Coeptis Therapeutics Holdings Inc (COEP) stock has risen 3.45% while the S&P 500 is down -0.45% as of 10:28 AM on Tuesday, Nov 21. COEP has risen $0.04 from the previous closing price of $1.16 on volume of 39,776 shares. Over the past year the S&P 500 is up 14.60% while COEP is down -47.14%. COEP lost -$3.65 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Coeptis Therapeutics Holdings Inc click here.

More About Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania. Click Here to get the full Stock Report for Coeptis Therapeutics Holdings Inc stock.